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Abstract 
 
In Africa the combination of non-communicable diseases, infectious diseases, exposure to 
environmental toxins and acute kidney injury related to trauma and childbirth are driving an 
epidemic of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Good registry 
data can inform the planning of renal services and can be used to argue for better resource 
allocation, audit the delivery and quality of care, and monitor the impact of interventions. 
Few African countries have established renal registries and most have failed due to resource 
constraints.  
In this paper we briefly review the burden of CKD and ESRD in Africa then consider the 
research questions which could be addressed by renal registries. We describe examples of 
the impact of registry data and summarise the sparse primary literature on country-wide 
renal replacement therapy (RRT) in African countries over the past 20 years. Finally, we 
highlight some initiatives and opportunities for strengthening research on ESRD and RRT in 
Africa. These include the establishment of the African Renal Registry and the availability of 
new areas for research. We also discuss capacity-building, collaboration, open access 
publication and the strengthening of local journals, all measures which may improve the 
quantity, visibility and impact of African research outputs. 
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I. Introduction: Chronic kidney disease and end-stage renal disease in 
Africa  
 
The World Health Organization (WHO) estimates that around 60% of global deaths are due 
to non-communicable diseases (NCDs),1 with most occurring in low- and middle-income 
countries (LMICs). Africa is a continent consisting of 54 low- and middle-income countries, 
home to a population of 1.17 billion people. Many of these countries are facing the triple 
burdens of infections, NCDs and injuries. There are insufficient studies on NCDs in Africa and 
there have been calls for more research to be conducted in this area.2, 3 Based on the 
available evidence, NCDs are already responsible for more than three-quarters of deaths in 
most North African countries (Figure 1)4 and while communicable diseases still predominate 
in sub-Saharan African regions, NCDs have been predicted to become the leading cause of 
death by 2030.5 
 
[Figure 1 – Heat map of NCD deaths by country in Africa] 
 
In LMICs, a disproportionate number of NCD deaths occur among younger people4 who are 
at the peak of their economic productivity. This has serious economic consequences for 
families and communities. Healthcare costs for chronic diseases can drain household 
resources and result in the loss of breadwinners, thereby contributing to the persistence of 
poverty and the lack of economic growth in many African countries.  
 
The World Health Assembly has endorsed the WHO Global Action Plan for the Prevention 
and Control of NCDs 2013-20206. The targets for this important initiative include a 25% 
reduction in premature mortality from NCDs by 2025. While kidney disease is not explicitly 
mentioned, the actions which are planned have the potential to make a significant impact 
on the burden of chronic kidney disease (CKD). The modifiable risk factors for NCDs which 
will be targeted are tobacco use, physical inactivity, unhealthy diet (including the reduction 
of salt intake) and the harmful use of alcohol. These behaviours are typically established 
during adolescence or young adulthood, and therefore interventions aimed at young people 
are especially important in Africa, which has the world’s youngest population.  
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The NCD epidemics of diabetes and cardiovascular disease (CVD) are well known, but the 
associated epidemics of CKD and end-stage renal disease (ESRD) have not received similar 
attention. In Africa, the combination of large increases in NCDs, a high burden of infectious 
diseases, exposure to numerous environmental toxins and high rates of acute kidney injury 
(AKI) related to trauma and childbirth mean that the incidence of CKD and ESRD is likely to 
be at least as high as is reported elsewhere.7, 8 Diabetic nephropathy is a leading cause of 
ESRD globally, and also in Africa9. The number of adults with diabetes in sub-Saharan African 
is projected to increase from 19.8 million in 2013 to 41.5 million in 2035.9, 10 Other 
important risk factors for CKD in the African region include hypertension and infection-
related renal disease. The number of people with HIV in sub-Saharan Africa exceeds 25 
million 11 and this contributes greatly to CKD in this region.12 
 
The worldwide prevalence of CKD in adults is approximately 10-13%13, 14 but there is little 
published data from most African countries.12, 15, 16 A recent systematic review12 highlighted 
the need for more studies of good quality from African countries. Based on 18 medium-
quality and three high-quality studies the population prevalence of CKD in sub-Saharan 
Africa was estimated at 13.9%.12 This estimate summarises data on 44 145 individuals from 
13 countries. However, these crude prevalence rates mask a higher rate of CKD in African 
countries. For example, when the age distribution of the populations is taken into account 
(www.wdi.worldbank.org), the crude prevalence of CKD in South Africa would be expected 
to be only two thirds that of the UK if it had the same population age distribution.  
 
[Figure 2 – Population pyramid for Africa] 
 
About 360 million Africans are between the ages of 10 and 24 (Figure 2).4 By 2050, they will 
have aged and, if they develop NCDs at the current rate, this will place a huge additional 
burden onto poorly-resourced health systems.  
 
The most serious sequelae of CKD are heart disease, stroke and progressive loss of renal 
function with development of ESRD. Again, there is a dearth of good data from most African 
countries. The annual incidence of ESRD in North African countries has been estimated at 
150 per million population (pmp).17, 18 Anand et al.19 have modelled the incidence of ESRD in 
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developing regions and predicted an annual incidence of 239 pmp in people with diabetes 
and hypertension living in sub-Saharan Africa.  
 
Renal replacement therapy (RRT) in the form of dialysis or transplantation is the treatment 
for ESRD. In most countries, especially LMICs, the incidence of RRT will not be the same as 
the incidence of ESRD, as it is a composite of both the disease rate and the access that 
affected people have to dialysis and transplantation services. Another measure that is 
important to consider is the number of people alive on RRT at any one point in time, the 
RRT prevalence, as this reflects the current human and economic burden of RRT on a 
society. Like RRT incidence, this is driven by the national burden of the disease and access to 
treatment (now and historically). It is also greatly affected by the survival rates on RRT. This 
effect of mortality is particularly relevant in low and middle income countries where chronic 
dialysis will be unaffordable to the majority and access to transplantation is limited.20 
 
The lack of renal registries and related publications means that there are very few reliable, 
current statistics on RRT in Africa. Published estimates are often based on old registry 
reports and unpublished data15, 21 but they do suggest that the provision of RRT services has 
been a low priority for the governments of most African countries. The prevalence of RRT is 
strongly associated with gross national income per capita.7 Most African patients with ESRD 
are unable to access RRT and are treated conservatively. Liyanage et al.22 estimate that 
there are at least 432 000 people in Africa requiring RRT but not receiving it. Where services 
are available, patients and their families generally pay out of pocket and most are unable to 
afford dialysis treatment beyond the first few months.23  
 
Against this background, we consider which questions can be answered by national renal 
registries. We then summarise the existing research outputs from African renal registries 
and highlight some initiatives and opportunities for strengthening research on ESRD and 
RRT in Africa. 
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II. Which questions can be answered by renal registries? 
 
Renal registries collect a well-defined set of health and demographic data from patients on 
RRT over many years with the aim of generating information on the causes and incidence of 
ESRD, and information on the prevalence, treatment and outcomes of patients on RRT. A 
minimum dataset would include information on the numbers of patients on each treatment 
modality, the numbers starting or ending treatment each year, and basic demographic 
information on each patient. Most registries will report data at least annually, providing a 
snapshot of RRT in a country or region as at 31 December of each year. 
 
In Africa, published registry data could be used to improve awareness of the as yet under-
appreciated epidemic of CKD/ESRD and would provide critical information to support the 
planning, delivery and evaluation of renal services. Discrepancies in the provision of services 
within and between countries could be highlighted and this may encourage governments to 
allocate more resources for the treatment of ESRD.24  Registry data can also aid in 
identifying the most important causes of renal disease in each country and thereby guide 
efforts to prevent, detect and treat the earlier stages of CKD. Table 1 summarises the 
questions that might be readily answered using data collected by renal registries.  
 
[Table 1. Questions that can be addressed by renal registries.]  
 
 
III. The impact of renal registries 
 
Registries have a key role to play in improving the health of populations, from identifying 
sub-groups with reduced access to treatment or poor outcomes, to monitoring the adoption 
and impact of evidence-based interventions. This role can be encapsulated in the term 
“translational public health research” (Figure 3) and is something registries have been doing 
to differing degrees for years, and in some instances with great impact. In this section, we 
provide selected examples of the impact of renal registries in African countries and beyond. 
 
   7 
 
[Figure 3 - Translational public health research applied to renal registries, adapted from 
reference 25.] 
 
Tunisia: Since its establishment in 199024 the Tunisian dialysis registry has influenced 
decisions to increase the number of nephrologists, develop a new transplant programme, 
start new dialysis units and develop a kidney disease prevention programme. The rate of 
new patients starting RRT in Tunisia increased from 82 per million population (pmp) in 1992-
1993 to 159 pmp in 2000-2001 and remains around this level.26 Of note, the registry data 
was able to identify three regions reporting particularly low treatment rates in the elderly, 
which may have reflected regional obstacles to treatment.24 
 
South Africa: The first report of the newly established South African Renal Registry was 
published in 2014 (December 2012 data),27 nearly 20 years after the previous SA Dialysis 
and Transplant Registry was last published. The report revealed a markedly uneven 
distribution of RRT across provinces and large differences in RRT rates between the public 
and private healthcare sectors (73 vs. 620 pmp). The release of the report attracted 
prominent media coverage28 and led to the national health minister convening a national 
summit on “An effective approach to chronic kidney disease in South Africa” in March 2015. 
It is hoped that a comprehensive approach and more resources will eventually flow from 
this initiative.  
 
Thailand: In Thailand, data from the Thai Renal Registry was instrumental in building the 
case for the “PD First” programme29 which, from 2008, saw a marked increase in access to 
peritoneal dialysis as the initial modality of treatment under their national healthcare 
insurance, Universal Coverage. Such rapid expansion in a country with areas of considerable 
poverty could have led to unintended negative consequences for some patients, so it was 
important that the Registry could provide essential quality assurance data on peritonitis 
rates and PD technique survival.30 
 
Malaysia: Established in the early 1990s, the National Renal Registry of the Malaysian 
Society of Nephrology (www.msn.org.my) is another very impressive renal registry. In 
addition to the basic data on treatment rates and modality, they report annually on the 
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attainment of quality standards, patient reported outcomes and renal biopsy data. They also 
provide an excellent example of how registry data was used to argue for increased funding 
of RRT as their country’s national wealth increased.31  
 
South America: The Latin American Dialysis and Transplant Registry has demonstrated that 
it is possible to establish and maintain a continental renal registry in difficult economic 
conditions.32 Established in the early 1990s, this pan-Latin American partnership has 
contributed to the development of national registries and allowed countries to report their 
treatment rates and outcomes in the context of geographically, culturally and economically 
similar neighbours, challenging treatment modality preferences and highlighting the 
importance of primary and secondary prevention in CKD.32 
 
Other examples: While there are many examples of renal registries delivering health 
improvements in high income countries, two are particularly noteworthy.  
 
The DOPPS Practice Monitor: This initiative in the USA (www.dopps.org/dpm) provides rich 
insights into trends in care delivery by using a sampling approach to study secondary 
outcomes and without collecting data on every patient in every dialysis unit. Topics like 
vascular access, bone mineral disorder and blood transfusion rates have been the focus of 
specific reports.33-35  
 
UK Renal Registry: It is becoming increasingly possible to use registries to provide the follow 
up for interventional studies and randomised controlled trials, an approach known as 
“efficient study design”. In the UK the effectiveness of a laboratory-level intervention that 
flags people with declining kidney function to prompt referral to a nephrologist is being 
evaluated. The outcome measure, percentage of patients presenting late to a nephrologist, 
has been routinely collected by the UK Renal Registry for years, giving robust baseline trend 
data and increasing power. Such registry-based pragmatic trials enable evidence to be 
gathered on the impact of new complex interventions. In a similar way, the UK Renal 
Registry is beginning to work with clinical trials units to design and deliver efficient 
individual-level randomised trials.25 
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IV. African renal registries: registry reports and related publications 
 
A few renal registries, the majority from North Africa, have been established in African 
countries. Reports have not been published regularly. The earliest reports are from Egypt 
and Tunisia in 1975, followed by South Africa in 1977, and thereafter by Libya, Algeria and 
Morocco.  
 
North African registries: The Egyptian Renal Registry first reported data from 199636 and 
the last reported data is from 2008.37 The Tunisian registry, established in 1990,24 was 
located in the Ministry of Public Health and achieved 100% coverage as the registration of 
patients was linked to reimbursement. However, the registry stopped functioning after 
2011. In Morocco, the Moroccan Registry for End-stage Renal Disease (Magredial, 
http://www.nephro-maroc.org) was established in 2006 by the Ministry of Health in 
collaboration with the Moroccan Society of Nephrology and the Agence de Biomédecine. Its 
first and only report was published in 2008.38 
 
Other African registries: The Nigerian Renal Registry was conceived 20 years ago but the 
use of complex questionnaires limited participation.  A simplified version was introduced in 
2014 and data from a few participating centres was presented at the 2015 Nigerian 
Association of Nephrology meeting (F Arogundade, personal communication). The South 
African Dialysis and Transplant Registry, established in 1977, stopped functioning due to lack 
of resources after reporting 1994 data. It has been re-established as the South African Renal 
Registry (http://www.sa-renalsociety.org/registry.asp), with its first report providing an 
analysis of 2012 data on RRT across the country.27 
 
Table 2 summarises the African publications since 1996 which have reported national data 
on ESRD treated with RRT. Registry reports and other primary research publications 
reporting country-wide data have been included. 
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[Table 2. African publications reporting national data on RRT over the last 2 decades.]  
 
In addition, there are published reports from regions or districts within a country such as 
those from Egypt39, 40 and Algeria.41 Data from North African countries have also been 
published in the ERA-EDTA Registry Annual Reports over a number of years (Table 3). Note 
that the 2014 Tunisian data describes the Sfax region only. 
 
[Table 3. Contributions of data to the ERA-EDTA Registry by North African countries.] 
 
 
 
V. Initiatives and opportunities for strengthening research on ESRD and 
RRT in Africa 
 
 
This section touches on a number of issues which have the potential for strengthening 
research and publication in the area of ESRD and RRT in Africa. 
 
 
i. Establishing national renal registries 
 
Establishing a national renal registry is a vital first step for every country which offers 
maintenance dialysis and transplantation. In several African countries nephrologists have 
established renal registries but most of these efforts have not been sustainable, mostly 
because of resource constraints.  
 
The African Renal Registry initiative 
 
Recognising the need for renal registries in many African countries, the African Association 
of Nephrology (AFRAN) and the African Paediatric Nephrology Association (AFPNA) have 
now embarked on the establishment of a continental “African Renal Registry”.42 At the 
World Congress of Nephrology in Cape Town in March 2015, AFRAN and AFPNA formally 
established the African Renal Registry which will utilize the Web-based platform of the 
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South African Renal Registry. Participating countries will share a stable, common technology 
platform and a common data dictionary which will facilitate joint analyses and comparisons 
between countries. Each country will retain full control over their own data and be free to 
report their country-specific findings. The Registry is currently being piloted in selected 
African countries.  
 
Countries participating in the African Renal Registry are expected to obtain ethics approval, 
and preferably a waiver of individual consent. Registries that require individual informed 
consent achieve only partial enrolment and a good case can be made for obtaining waivers 
from institutional health research ethics committees so that individual consent does not 
have to be obtained.43 As long as proper safeguards are in place to secure patient data, this 
risk can be balanced against the benefit of obtaining a more complete picture of ESRD and 
RRT in a country or region. The South African, UK, Scottish and French registries all operate 
using a waiver of consent.  
 
 
ii. Improving research outputs 
 
Overall health research output in the WHO African Region has improved in recent years but 
remains at a low level, increasing from 0.7% of worldwide health research publications in 
2000 to 1.3% in 2014.44 National gross domestic product is an independent predictor of 
publication outputs. South Africa, Nigeria and Kenya contributed more than half of all the 
papers listed in Pubmed during this period but Gambia, Malawi and Guinea-Bissau were the 
leading countries when output was normalised for gross domestic product.44 
 
Building capacity 
 
There have been many initiatives to improve research capacity in Africa. For example, the 
Initiative to Strengthen Health Research Capacity in Africa (ISHReCA) is an organisation of 
African health researchers formed in 2007 to strengthen Africa’s capacity to carry out high 
quality health research and translate findings into policy and practice.45 ISHReCA provides a 
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platform for discussion of health research needs and advocacy for governmental and 
societal support.  
 
Of interest to researchers working with renal registries is that there has been a recent 
increase in epidemiological research productivity in the WHO/AFRO region. This is 
associated with the number of epidemiology programmes and the burden of HIV/AIDS in 
particular countries. More capacity building and training initiatives in epidemiology and 
biostatistics are required to advance research and address the public health challenges 
facing the continent.46 Initiatives like the Chronic Disease Initiative in Africa and the 
Collaboration for Evidence based Health in Africa are putting dedicated investment into 
advancing capacity development and the conduct of relevant research on NCDs in Africa. 
Dedicated efforts are also continuing to develop biostatistics capacity for research.47 
 
Developing effective collaborations 
 
Collaboration with high-income country (HIC) investigators and institutions can bring 
valuable expertise, funding, and other resources to Africa. However, much of the research is 
led, funded, and published by HIC researchers without equal collaboration from their 
African colleagues.48 Data ownership is also often a contentious issue. Good partnerships 
address the priority health problems of a country or region and involve real capacity 
building. African researchers have to take an active role in directing these collaborations to 
set the research agenda, maximize the benefits and minimize the potential harm of these 
relationships.49 
 
African researchers collaborate most frequently with partners in the USA (39,292 research 
papers in Web of Science between 2000 and 2012), France (31,421), the UK (25,753), 
Germany (13,879) and Canada (7,604).50 Research collaboration between different African 
countries is poor. A study of collaboration among the 15 countries of the Southern African 
Development Community (SADC) and between the SADC and the rest of Africa found that 
only 3% of SADC papers during 2005-2008 were jointly authored by researchers from two or 
more SADC countries, and only 5% of papers were jointly authored with researchers from 
African countries outside the SADC.51 Similar findings were reported from West African 
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countries, who also cooperated less with each other and with other African countries than 
they did with developed ones.52 Collaboration between researchers from different African 
countries must be pursued vigorously as it is likely to result in improvements in both the 
quantity and quality of research. 
 
The recent establishment of the African Renal Registry presents a new opportunity for 
collaboration between different African countries. Joint analyses and reporting is facilitated 
by the use of a shared IT platform and a common data dictionary.42 Another initiative which 
may foster collaboration is the establishment of the East African Kidney Institute at the 
University of Nairobi (http://chs.uonbi.ac.ke/node/9408). The Institute was conceived as a 
centre of excellence for training and research, and actively seeks mutually beneficial 
collaborations. It is supported by the government of Kenya and the African Development 
Bank.  
 
Access to the research literature 
 
Various initiatives have improved the access to research information for African researchers. 
HINARI (Health Internetwork Access to Research Initiative, www.healthinternetwork.org) is 
a partnership between the World Health Organization and scientific publishers which 
provides access to up to 13000 journals and 47000 e-books for institutions in more than 100 
low-income countries.53 
 
The International Network for the Availability of Scientific Publication (INASP) is an NGO 
working with a network of partners to improve access and use of research information.54 
INASP has facilitated access via the Programme for the Enhancement of Research 
Information (PERI) and the Strengthening Research and Knowledge Systems (SRKS, 
http://www.inasp.info/en/work/what-we-do/programmes/srks/) programmes, provided 
training for librarians, and supported the visibility of African research through the Journals 
Online (http://www.inasp.info/en/work/journals-online/) and African Journals Online 
(http://www.ajol.info/) platforms. Other initiatives include JSTOR (http://www.jstor.org/), 
the digital library which provides free or low cost access to over 1500 institutions in Africa 
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and other developing countries, and the Directory of Open Access Journals (DOAJ, 
https://doaj.org/). 
  
The Arcadia report55 explored researchers’ access to scholarly materials at universities in 
east and southern Africa and found that the provision of online resources approached that 
of major European universities although affordability remained a challenge. The report 
recommended improved promotion of available resources and skills development for end-
users.55 
 
Internet access is critical in accessing these electronic resources and continues to improve, 
notably with the installation of high-speed undersea fibre-optic cables and the growing 
availability of mobile broadband.56  
 
New research opportunities 
 
Setting research priorities: The global imbalance of research funding was recognised in the 
1990s, when 90% of biomedical research funds were being spent on 10% of the disease 
burden.57 Despite some progress, this marked disparity persists58 and a systematic priority 
setting approach is required to address this. One of the case studies of the Essential 
National Health Research initiative was South Africa, which identified priority disease areas 
that are frequently associated with kidney disease (trauma, HIV, diarrhoeal illnesses and 
malaria).59 Two of the characteristics for priority setting are best delivered by registries – 
“continuous burden of disease analysis” and “indicators of performance to track impact” – 
highlighting the key role of registries in translational public health research. The report also 
highlights the importance of priorities being “user driven” and including participants from all 
sectors.59 There are now several examples, mainly from high-income countries, of the views 
of people with kidney disease being included in the setting of kidney research priorities.60 
African researchers should conduct similar studies as it is likely that the issues facing people 
with kidney disease in low- and middle-income countries will be situation-specific. 
 
Research synthesis: In Africa, especially, the scarce resources for health research must be 
optimally utilised. Before embarking on new research, robust synthesis of relevant existing 
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research should be done to identify areas where new evidence is needed.61 This is an 
essential step to avoid wasteful duplication and to reverse the trend of conducting and 
publishing small, low-impact studies. Key research priorities can be delineated through the 
combination of using systematic reviews and engaging with stakeholders. The recognition of 
the importance of research synthesis is reflected in the increasing calls for funding agencies 
to provide resources for conducting systematic reviews of existing research relevant to the 
developing world, as a scientific and ethical requirement, before investing in new 
research.61, 62  
 
Knowledge translation: Promotion of the use of research to inform policy and practice is 
integral to the advancement of evidence based practices. A lot of research is available on 
strategies to promote the use of research in decision making63 and policymakers and 
researchers need to draw on this to ensure better health outcomes. Integral to these 
strategies is timely production of relevant research, access to research, engagement 
between decision makers and researchers, and collaboration. 
 
Genetic studies and the H3Africa project: The H3Africa Kidney Disease Research Network is 
a large initiative to study chronic kidney disease in sub-Saharan Africa and has a very strong 
focus on increasing the capacity for genetics and genomics research among African 
scientists. The network is part of the Human Heredity and Health in AfricaConsortium 
(http://h3africa.org/) and is recruiting patients in Ghana, Nigeria, Ethiopia, and Kenya, and 
analysing environmental and genetic factors associated with CKD. It is envisaged that 4000 
participants with CKD and 4000 controls will be recruited, as well as 50 families with 
hereditary glomerular disease.64, 65 The capacity-building goals of this ambitious project are 
already being realised: 5 doctors have completed a 2-year training program on clinical 
research methods and biostatistics, 5 biomedical scientists are training in laboratory 
genomics, 1 masters-level student is training in biochemistry, 3 scientists are training in 
bioinformatics, and 2 research administrators are training in programme management.65 
 
Geographic information systems: The “geographic approach” integrates geographic 
information into problem solving. Geographic information systems (GIS) can be used for 
modelling and mapping disease, predicting future disease risks and analysing the 
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distribution of resources and services. ESRD and RRT are uniquely suited to analysis by 
geographic methods as patients require expensive care in specialized facilities by highly 
skilled personnel. The distribution of new cases could identify high prevalence “hotspots” 
which could guide efforts to identify and address risk factors. There may be inadequate 
numbers or maldistribution of healthcare professionals, and long travelling times to dialysis 
facilities may compromise quality of life and clinical outcomes. GIS approaches can be 
applied to study the interplay between ethnicity, poverty, rural residence and access to RRT. 
Mismatching between resources and the patient population needs can be identified and 
interventions appropriately targeted.66 
 
To establish whether African researchers are employing GIS approaches to studying renal 
disease in Africa we conducted searches (in July 2016) of Scopus, EbscoHost Academic 
Premier and Web of Science using the search strings (GIS OR geographic* information 
system* OR global positioning system*) AND (kidney OR renal OR nephr*). The search 
yielded no studies in the area of nephrology from Africa which have employed a geographic 
approach. 
 
 
iii. Ensuring better visibility for African research, and strengthening African medical 
journals  
 
Existing African research is poorly visible and under-represented in international databases. 
In this section we consider what African researchers and African medical journals can do to 
improve the visibility and potential impact of their research. 
 
Publish ESRD/RRT data in peer-reviewed journals and embrace open access science 
 
Publish in peer-reviewed journals: Registry data, whether country-wide or regional, should 
be reported in peer-reviewed journals to ensure wide dissemination and increase the 
discoverability of the research. Data which lies only within registry reports (and not in 
medical journals) can easily be missed and therefore not have the desired impact.  
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Embrace open access publication: "Open access" (OA) refers to unrestricted online access 
to research publications, removing price barriers and most licensing restrictions. A recent 
review67 demonstrated the positive correlation between OA publication and citations, 
scientific impact, media coverage, potential collaborators, job opportunities, and funding 
opportunities. By publishing their research as OA articles, African researchers are more 
likely to have their work discovered and cited. Other actions which can easily be taken to 
increase the visibility and impact of their work include depositing copies of published 
articles and preprints of new manuscripts in a public repository, sharing datasets, and pre-
registering clinical trials in a registry such as the Pan African Clinical Trials Registry (PACTR, 
http://www.pactr.org/).67  
 
Many institutions still create pressure on researchers to publish in higher impact factor 
journals, which are often not open access. However, the limitations of journal-level metrics 
are increasingly being recognized and there are strong movements, like the San Francisco 
Declaration on Research Assessment (SF-DORA),68 which recommend that such metrics not 
be used to evaluate research outputs. More importance is being placed on the use of 
article-level metrics such as the h-index69 and alternative metrics based on the Social Web 
(altmetrics). Altmetrics like Tweets, article downloads, mentions on blogs, and media 
articles have helped to demonstrate the impact of open access publication. 
 
To date (July 2016) 46 African institutions have signed the Berlin Declaration on Open 
Access to Knowledge in the Sciences and Humanities, with Stellenbosch University the first 
African signatory in 2010. 
 
Strengthening African medical journals  
 
The current availability of robust open source platforms for publishing scholarly journals has 
greatly reduced the barriers to establishing and successfully operating a medical journal. 
The Open Journal Systems (OJS) and SciELO initiatives are of particular relevance for African 
journal editors. There are three nephrology journals based in Africa and these are briefly 
described in Table 4. In addition, many papers are published in the Saudi Journal of Kidney 
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Diseases and Transplantation (http://www.sjkdt.org) by North African authors. The African 
nephrology journals all use OJS, either directly or via the AJOL platform. 
 
[Table 4. African nephrology journals.] 
 
 
The Open Journal Systems platform: Open Journal Systems (OJS, http://pkp.sfu.ca) is an 
open source initiative of the Public Knowledge Project at the University of British Columbia. 
OJS is a free online journal management and publishing system which seeks to improve the 
quality of journal publishing by supporting every stage of the publishing process, from 
online submissions through to reviewing, online publication and indexing. The Public 
Knowledge Project estimates that over 9000 journals were using OJS in 2015.  
 
Scientific Electronic Library Online (SciELO): Since its inception in 1987 in Brazil, the online 
open access SciELO platform for scholarly publication has been implemented in 15 
countries, mainly in South America. SciELO aims to improve the quality, visibility, use and 
impact of the included journals. The journals comply with strict quality criteria and appear 
on the Thomson Reuters Web of Knowledge platform as the SciELO Citation Index. SciELO 
South Africa (SA) became a full member of the SciELO Network Global Portal in 2012. There 
are currently 60 journals on the SciELO SA platform, including 17 health sciences journals. 
 
Using XML in the publishing process: Extensible Markup Language (XML) is an “enabling 
technology” which improves the discoverability and accessibility of online research. XML 
tags the content of articles allowing publishers to use a single source file to create different 
formats of the same article such as PDF, html, ePub or print formats. The submission of XML 
metadata is also required by online vendors, who make articles searchable for a much 
bigger audience. For example, CrossRef (www.crossref.org) allows readers to access a paper 
that an article cites by clicking on the citation in the reference section. CrossRef does this by 
assigning each article a unique Digital Object Identifier (DOI) and linking this to the article’s 
XML metadata supplied by the publisher.70 
 
African Journal Partnership Program: The African Journal Partnership Project (AJPP, 
http://ajpp-online.org) is another initiative which provides support for African journals. It is 
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sponsored by the US National Library of Medicine and the US Fogarty International Center, 
and partners African journals with leading US- and European-based journals.71 Initially, 
African Health Sciences was paired with BMJ, Ghana Medical Journal with The Lancet, 
Malawi Medical Journal with JAMA, and Mali Médical with Environmental Health 
Perspectives and the American Journal of Public Health. There are currently nine African 
journals paired with six Northern partners. Since joining the project, participating journals 
have reported a sharp increase in the number of manuscripts received, lower acceptance 
rates and better overall quality in the research published.72  
 
 
 
Conclusions 
It is clear that to be successful a renal registry must fulfil the needs of its key stakeholders. 
These needs will vary from country to country and may evolve over time, but they tend to 
begin with informing the planning of services and monitoring access to treatment then 
progressing to national audit and quality assurance. Studying disease and treatment rates 
for auditing and service planning involves elements of epidemiology, but there are many 
new exciting opportunities to utilise registry infrastructure to do research and efficiently 
generate new evidence on treatment effectiveness. 
There are, of course, many challenges to setting up and maintaining a renal registry, even if 
all relevant stakeholders have been engaged. Sustainable adequate funding is crucial if the 
necessary infrastructure and expertise is to be established, developed and retained. African 
nephrologists have recognised the vital role that registries can play and, through the African 
Renal Registry and other initiatives, are seeking to create opportunities for efficiencies and 
synergies from working together to establish and run renal registries, and conduct research 
on ESRD in Africa. Through collaboration locally and globally registries have the potential to 
greatly improve the outcomes of people with kidney disease in all of our countries. 
Annual reports and other scholarly outputs from renal registries need to be discoverable 
and accessible to have the greatest impact. In this regard, African nephrologists should 
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embrace open access publication and African editors should take advantage of the robust 
open source platforms which are available for establishing and operating medical journals.   
   21 
 
References 
 
1. Alwan A. Global status report on noncommunicable diseases 2010. Geneva: World Health 
Organization; 2011.  
2. Dalal S, Beunza JJ, Volmink J, et al. Non-communicable diseases in sub-Saharan Africa: what 
we know now. Int. J. Epidemiol. 2011;40:885-901. 
3. Perico N, Remuzzi G. Chronic kidney disease in sub-Saharan Africa: a public health priority. 
The Lancet Global Health. 2014;2:e124-e125. 
4. Naik R, Kaneda T. Noncommunicable diseases in Africa: youth are key to curbing the 
epidemic and achieving sustainable development. Washington, DC: Population Reference 
Bureau; 2015. http://www.prb.org/pdf15/ncds-africa-policybrief.pdf.  
5. Marquez PV, Farrington JL. The challenge of non-communicable diseases and road traffic 
injuries in Sub-Saharan Africa: an overview. Washington, DC: The World Bank; 2013.  
6. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. 
Geneva, Switzerland: World Health Organization; 2013. 
http://www.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1.  
7. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, 
social, and economic implications. Kidney Int. Suppl. 2005:S7-S10. 
8. White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in 
provision of renal replacement therapy? Bull. World Health Organ. 2008;86:229-237. 
9. Noubiap J, Naidoo J, Kengne AP. Diabetic nephropathy in Africa: a systematic review. World J 
Diabetes. 2015;6:759-773. 
10. Aguiree F, Brown A, Cho NH, et al. IDF Diabetes Atlas: sixth edition. Basel, Switzerland: 
International Diabetes Federation; 2013. http://hdl.handle.net/10536/DRO/DU:30060687.  
11. AIDS by the numbers. Geneva, Switzerland: Joint United Nations programme on HIV/AIDS 
2016. http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-numbers-
2016_en.pdf.  
12. Stanifer JW, Jing B, Tolan S, et al. The epidemiology of chronic kidney disease in sub-Saharan 
Africa: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e174-e181. 
13. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on 
the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88:950–957. 
14. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease–a systematic 
review and meta-analysis. PLoS ONE. 2016;11:e0158765. 
15. Naicker S. End-stage renal disease in Sub-Saharan Africa. Kidney Int. Suppl. 2013;3:161-163. 
16. Swanepoel CR, Wearne N, Okpechi IG. Nephrology in Africa—not yet uhuru. Nat Rev 
Nephrol. 2013;9:610-622. 
17. Barsoum RS. Chronic kidney disease in the developing world. N. Engl. J. Med. 2006;354:997-
999. 
18. Barsoum RS. Burden of chronic kidney disease: North Africa. Kidney Int. Suppl. 2013;3:164-
166. 
19. Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage renal 
disease and use of therapy. PLoS ONE. 2013;8:e72860. 
20. El Nahas M. The global challenge of chronic kidney disease. Kidney Int. 2005;68:2918-2929. 
21. Benghanem Gharbi M. Renal replacement therapies for end-stage renal disease in North 
Africa. Clin. Nephrol. 2010;74:S17-19. 
22. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney 
disease: a systematic review. Lancet. 2015;385:1975-1982. 
23. Arogundade F, Sanusi A, Hassan M, Akinsola A. The pattern, clinical characteristics and 
outcome of ESRD in Ile-Ife, Nigeria: Is there a change in trend? Afr. Health Sci. 2011;11:594-
601. 
   22 
 
24. Counil É, Cherni N, Kharrat M, Achour A, Trimech H. Trends of incident dialysis patients in 
Tunisia between 1992 and 2001. Am. J. Kidney Dis. 2008;51:463-470. 
25. Caskey FJ, Cullen R. UK Renal Registry 18th Annual Report: Introduction. Nephron Clin. Pract. 
2016;132:1-8. 
26. ERA-EDTA Registry 2014 Annual Report. Amsterdam: Department of Medical Informatics, 
Academic Medical Centre; 2014.  
27. Davids MR, Marais N, Jacobs JC. South African Renal Registry Annual Report 2012. Cape 
Town: South African Renal Society; 2014.  
28. Fokazi S. 70% of kidney patients sent home to die, says prof. Cape Argus. Cape Town: 
Independent Media; 2014. 
29. Morad Z, Choong HL, Tungsanga K, Suhardjono. Funding renal replacement therapy in 
southeast Asia: building public-private partnerships in Singapore, Malaysia, Thailand, and 
Indonesia. Am. J. Kidney Dis. 2015;65:799-805. 
30. Dhanakijcharoen P, Sirivongs D, Aruyapitipan S, Chuengsaman P, Lumpaopong A. The "PD 
First" policy in Thailand: three-years experiences (2008-2011). J. Med. Assoc. Thai. 2011;94 
Suppl 4:S153-161. 
31. Lim TO, Goh A, Lim YN, Morad Z. Use of renal registry data for research, health-care planning 
and quality improvement: what can we learn from registry data in the Asia-Pacific region? 
Nephrology. 2008;13:745-752. 
32. Rosa-Diez G, Gonzalez-Bedat M, Pecoits-Filho R, et al. Renal replacement therapy in Latin 
American end-stage renal disease. Clin Kidney J. 2014;7:431-436. 
33. Fuller DS, Zepel L, Bieber BA, Robinson BM, Pisoni RL. Hemodialysis facility variation in 
hospitalization and transfusions using Medicare claims: the DOPPS Practice Monitor for US 
dialysis care. Am. J. Kidney Dis. 2016;67:337-340. 
34. Tentori F, Zepel L, Fuller DS, et al. The DOPPS Practice Monitor for US dialysis care: PTH 
levels and management of mineral and bone disorder in US hemodialysis patients. Am. J. 
Kidney Dis. 2015;66:536-539. 
35. Tentori F, Fuller DS, Port FK, Bieber BA, Robinson BM, Pisoni RL. The DOPPS Practice Monitor 
for US dialysis care: potential impact of recent guidelines and regulatory changes on 
management of mineral and bone disorder among US hemodialysis patients. Am. J. Kidney 
Dis. 2014;63:851-854. 
36. Afifi A, Karim MA. Renal replacement therapy in Egypt: first annual report of the Egyptian 
Society of Nephrology, 1996. East. Mediterr. Health J. 1999;5:1023-1029. 
37. Afifi A. Egyptian Renal Registry 9th Annual Report. Cairo: Egyptian Society of Nephrology and 
Transplantation; 2008. http://www.esntonline.com/content/downloads/registry/2008.pdf. 
22 August 2016 
38. Magredial. Moroccan registry for end-stage renal disease Morocco: Moroccan Ministry of 
Health, the Moroccan Society of Nephrology and the Agence de Biomédecine; 2008. 
http://nephro-maroc.org/wp-
content/uploads/2016/03/ProtocoleMagredial_NOV_2008.pdf.  
39. El-Minshawy O. End-stage renal disease in the El-Minia governorate, upper Egypt: an 
epidemiological study. Saudi J Kidney Dis Transpl 2010;22:1048-1054. 
40. El-Arbagy AR, Kora MAE-A, El-Barbary HS, Gabr HM, Selim AAE-M. Prevalence of end stage 
renal disease in Menoufia governorate. Nature and Science. 2015;13:154-158. 
41. Bouhabel A, Laib Z, Hannache K, Aberkane A. [Renal replacement therapy by hemodialysis in 
Constantine (Algeria)]. Nephrologie & Therapeutique. 2014;10:39-43. 
42. Davids MR, Eastwood JB, Selwood NH, et al. A renal registry for Africa: first steps. Clin Kidney 
J. 2016;9:162-167. 
43. Ingelfinger J, Drazen J. Registry research and medical privacy. N. Engl. J. Med. 
2004;350:1452. 
   23 
 
44. Uthman OA, Wiysonge CS, Ota MO, et al. Increasing the value of health research in the WHO 
African Region beyond 2015—reflecting on the past, celebrating the present and building 
the future: a bibliometric analysis. BMJ Open. 2015;5:e006340. 
45. Whitworth JA, Kokwaro G, Kinyanjui S, et al. Strengthening capacity for health research in 
Africa. The Lancet. 2008;372:1590-1593. 
46. Nachega JB, Uthman OA, Ho Y-S, et al. Current status and future prospects of epidemiology 
and public health training and research in the WHO African region. Int. J. Epidemiol. 
2012;41:1829-1846. 
47. Machekano R, Young T, Conradie W, Rusakaniko S, Thabane L. Workshop report: building 
biostatistics capacity in Sub-saharan Africa-taking action. Pan Afr Med J. 2015;21:167. 
48. Edejer T. North-South research partnerships: the ethics of carrying out research in 
developing countries. Br. Med. J. 1999;319:438. 
49. Chu KM, Jayaraman S, Kyamanywa P, Ntakiyiruta G. Building research capacity in Africa: 
equity and global health collaborations. PLoS Med. 2014;11:e1001612. 
50. Adams J, Gurney K, Hook D, Leydesdorff L. International collaboration clusters in Africa. 
Scientometrics. 2014;98:547-556. 
51. Boshoff N. South–South research collaboration of countries in the Southern African 
Development Community (SADC). Scientometrics. 2010;84:481-503. 
52. Mêgnigbêto E. International collaboration in scientific publishing: the case of West Africa 
(2001–2010). Scientometrics. 2013;96:761-783. 
53. Ochs M, Aronson B, Wu J. HINARI and AGORA: revolutionizing access to scientific 
information in the developing world. Serials. 2004;17. 
54. Powell A, Farrow E, Burnett P. Strategy, sustainability and quality: how INASP and its 
partners are strengthening access to research in Africa. IFLA WLIC 2014 - Lyon - Libraries, 
citizens, societies: confluence for knowledge. Lyon, France: International Federation of 
Library Associations and Institutions 2014. 
55. Harle J. Growing knowledge: access to research in east and southern African universities. 
London, UK: The Association of Commonwealth Universities; 2010. 
https://www.acu.ac.uk/focus-areas/arcadia-growing-knowledge.  
56. Stork C, Calandro E, Gamage R. The future of broadband in Africa. info. 2014;16:76-93. 
57. The 10/90 Report on Health Research 2000. Geneva: Global Forum for Health Research; 
2000.  
58. Evans JA, Shim JM, Ioannidis JP. Attention to local health burden and the global disparity of 
health research. PLoS ONE. 2014;9:e90147. 
59. Jacobs M. Priority setting for health research, the case of South Africa. Forum 3. Geneva, 
Switzerland: Global Forum for Health Research; 1999. 
60. Tong A, Chando S, Crowe S, et al. Research priority setting in kidney disease: a systematic 
review. Am. J. Kidney Dis. 2015;65:674-683. 
61. Wiysonge CS, Volmink J. Strengthening research capacity. Lancet. 2002;359:713. 
62. Young T, Garner P, Clarke M, Volmink J. Evidence-based health care and policy in Africa: 
past, present, and future. J. Clin. Epidemiol. 2016:in press. 
63. Oliver K, Innvar S, Lorenc T, Woodman J, Thomas J. A systematic review of barriers to and 
facilitators of the use of evidence by policymakers. BMC Health Serv. Res. 2014;14:1. 
64. Osafo C, Raji YR, Burke D, et al. Human Heredity and Health (H3) in Africa Kidney Disease 
Research Network: a focus on methods in Sub-Saharan Africa. Clin. J. Am. Soc. Nephrol. 
2015;10:2279-2287. 
65. Osafo C, Raji YR, Olanrewaju T, et al. Genomic approaches to the burden of kidney disease in 
Sub-Saharan Africa: the Human Heredity and Health in Africa (H3Africa) Kidney Disease 
Research Network. Kidney Int. 2016;90:2-5. 
66. Rodriguez RA, Hotchkiss JR, O'Hare AM. Geographic information systems and chronic kidney 
disease: racial disparities, rural residence and forecasting. J Nephrol. 2013;26:3-15. 
   24 
 
67. McKiernan EC, Bourne PE, Brown CT, et al. How open science helps researchers succeed. 
eLife. 2016;5:e16800. 
68. San Francisco declaration on research assessment: American Society for Cell Biology; 2012. 
http://www.ascb.org/dora/. 07 August 2016 
69. Hirsch JE. An index to quantify an individual's scientific research output. Proc. Natl. Acad. Sci. 
U. S. A. 2005:16569-16572. 
70. Hoekman A. Journal publishing technologies: XML: Michigan State University; 2016. 
https://msu.edu/~hoekmana/WRA%20420/ISMTE%20article.pdf. 29 July 2016 
71. Goehl TJ, Flanagin A. Enhancing the quality and visibility of African medical and health 
journals. Environ. Health Perspect. 2008;116:A5. 
72. Ndlovu D-F. Africa’s medical journals see rapid recovery: Research Professional; 2012. 
http://www.researchresearch.com/news/article/?articleId=1161922. 07 August 2016 
73. Masri M, Haberal M, Shaheen F, et al. Middle East Society for Organ Transplantation 
(MESOT) Transplant Registry. Exp. Clin. Transplant. 2004;2:217-220. 
74. Alashek WA, McIntyre CW, Taal MW. Provision and quality of dialysis services in Libya. 
Hemodial. Int. 2011;15:444-452. 
75. Alashek WA, McIntyre CW, Taal MW. Epidemiology and aetiology of dialysis-treated end-
stage kidney disease in Libya. BMC Nephrol. 2012;13:1. 
76. Albitar S, Bourgeon B, Genin R, et al. Epidemiology of end-stage renal failure in Reunion 
Island (results from the registry of the Indian Ocean Society of Nephrology). Nephrol. Dial. 
Transplant. 1998;13:1143-1145. 
77. Davids MR, Marais N, Balbir Singh GK, Jacobs JC. South African Renal Registry Annual Report 
2013. Cape Town: South African Renal Society; 2015.  
78. Davids MR, Balbir Singh GK, Marais N, Jacobs JC. South African Renal Registry Annual Report 
2014. Cape Town: South African Renal Society; 2016.  
79. Elhassan EA, Kaballo B, Fedail H, et al. Peritoneal dialysis in the Sudan. Perit. Dial. Int. 
2007;27:503-510. 
80. Elamin S, Obeid W, Abu-Aisha H. Renal replacement therapy in Sudan, 2009. Arab Journal of 
Nephrology and Transplantation. 2010;3:31-36. 
81. Ben MH. [Nephrology in Tunisia: From yesterday to now]. Nephrol. Ther. 2010;6:173-178. 
82. Rapport D'Activite Des Centres et Unites D'Hemodialyse, Annee 2010: Ministere de la Sante 
Publique, Tunisia; 2011.  
 
 
 
  
   26 
 
Table 1. Questions that can be addressed by renal registries. These can be related to (i) 
patients and their treatment and (ii) the resources available for RRT 
 
 
Patients, access to treatment, and outcomes 
 Incidence and aetiology of acute kidney injury (biopsy-proven or clinically diagnosed) 
 Dialysis therapy for - and outcomes of - acute kidney injury 
 Incidence and prevalence of ESRD (or stage 5 CKD) 
 Incidence and prevalence of patients accessing RRT 
 Distribution of patients and disparities in their access to RRT 
 - age, sex, ethnicity, socio-economic status 
 - geography – urban/rural, regional/provincial disparities 
 - economic factors – medical insurance, access to private vs. public sector services 
 - treatment modalities,  including the use of transplantation, automated PD and home HD 
 - access to medications such as erythropoietin, intravenous iron, immunosuppressives 
 Aetiology of ESRD 
 Co-morbid diseases - especially diabetes, HIV, hepatitis B and hepatitis C 
 Primary outcomes 
- patient survival 
- modality/technique survival 
 Other commonly reported outcomes 
- causes of death or reasons for cessation of treatment 
- hospitalizations 
- dialysis adequacy 
- vascular access in HD patients 
- laboratory data such as those related to anaemia management, bone-mineral disease, etc. 
- rejection episodes in transplant patients 
 Outcomes in sub-populations of interest 
- children 
- the elderly 
- people with HIV 
- people treated conservatively, without RRT 
 Newer outcomes – the patient experience 
- quality of life – both quantitative and qualitative data 
- employment 
 - travelling issues and distances to units (using geographic information systems approaches) 
Resources for RRT 
 Human resources – nephrologists, renal nurses, dialysis technologists 
 - numbers, distribution and demographics 
 - training, experience, formal qualifications 
 - nature of their practice (clinical nephrology, teaching, research) 
 Physical infrastructure – dialysis units and transplant centres 
 -  numbers, distribution, capacity, ownership, supervision 
 -  licensing authorities and licensing procedures 
 Technology and logistics  
 - availability of haemodiafiltration, automated PD, home HD 
` - dialysis water treatment systems, water quality testing 
 - maintenance and servicing of equipment 
 - availability and distribution of PD fluid (locally produced or imported) 
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 Costs and funding of treatment 
 - comparative costs of different modalities 
 - government support and funding 
 - funding from medical insurance, NGOs, other sources 
 - costs borne by the patient and his/her family 
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Table 2. African publications reporting national registry data over the last 2 decades. Registry reports and other primary research publications 
reporting country-wide data have been included. 
 
 
Author and 
year 
Country/region Last 
data 
Journal 
article 
Registry 
data 
reported 
Publication type Data reported Comments 
Afifi, 199936 Egypt 1996 Yes Yes Cross-sectional study Prevalence, aetiology, mortality First report by the Egyptian Society 
of Nephrology 
Afifi, 200837 Egypt 2008 No Yes Registry report Prevalence, aetiology, quality 
measures 
Presentation, available as a PDF file 
Masri, 
200473 
Egypt, Libya, 
Morocco, 
Sudan, Tunisia 
2003 Yes Yes Transplant registry 
report 
Transplant rates, donor types Data from the Middle Eastern 
Society of Transplantation Registry 
Alashek, 
201174 
Libya 2009 Yes No Cross-sectional study Prevalence, treatment centres, 
HR 
Detail on centres, staffing, infection 
control and quality measures 
Alashek, 
201275 
Libya 2010 Yes No Cross-sectional study 
plus prospective arm 
Incidence, prevalence, aetiology Incidence established via 1-year 
prospective arm 
Albitar, 
199876 
Reunion Island 1996 Yes Yes Registry report Incidence, prevalence, aetiology, 
mortality 
Data from the Indian Ocean Society 
of Nephrology registry 
Davids, 
201427  
South Africa 2012 No Yes Registry report Prevalence, aetiology, treatment 
centres 
First report of a new national 
registry 
Davids, 
201577 
South Africa 2013 No Yes Registry report Prevalence, aetiology, treatment 
centres 
 
Davids, 
201678 
South Africa 2014 No Yes Registry report Prevalence, aetiology, treatment 
centres 
 
Elhassan, 
200779 
Sudan 2007 Yes No Prospective cohort 
study 
Incidence, complications, 
mortality, treatment centres, HR 
First report of a new national PD 
programme 
Elamin, 
201080 
Sudan 2009 Yes No Cross-sectional study Prevalence, aetiology, treatment 
centres, quality measures 
 
Counil, 
200824  
Tunisia 2001 Yes Yes Observational study Incidence, aetiology An analysis of trends in incidence of 
RRT 1992-2001 
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Ben Maïz, 
201081 
Tunisia 2008 Yes Yes Review of 
nephrology in 
Tunisia 
Incidence, prevalence, 
treatment centres, HR 
 
Ministry of 
Health, 
201082 
Tunisia 2010 No Yes Registry report Prevalence, aetiology, mortality, 
treatment centres, HR 
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Table 3. Contributions of data to the ERA-EDTA Registry by North African countries. The dates 
refer to the dates of data collection. From reference 42. 
 
Country First and last data submissions Comments 
Algeria 1981 1997 No data submitted for 1994 
Egypt 1975 1996 No data for 1978-80, 1994-5 
Libya 1980 1996 No data for 1993-4 
Morocco 1995 1997  
Tunisia 1975 2014 No data for 1978-80, 1994, 1998-2000, 2006, 
2009-2013 
 
 
 
 
 
Table 4. African nephrology journals. The publication frequency reflects the number of issues 
published in recent years. 
 
Journal name 
and website address 
Start 
date 
Open 
access 
Issues 
per year 
Notes  
African Journal of Nephrology  - http://www.journals.ac.za/index.php/ajn/index 
 1997 Yes 1 Publication of the African Association of Nephrology 
Arab Journal of Nephrology and Transplantation - http://www.ajol.info/index.php/ajnt/index 
 2008 Yes 3 Publication of the Arab Society of Nephrology and Renal Transplantation 
African Journal of Paediatric Nephrology - http://www.ajol.info/index.php/ajpn/index 
 2014 No 2 Publication of the African Paediatric Nephrology Association 
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Figures 
 
 
Figure 1. Heat map of deaths due to noncommunicable diseases in Africa in 2012.4 
 
 
Figure 2. Population pyramid for Africa.4 
 
 
Figure 3. Translational public health research applied to renal registries. Red arrows indicate 
sites on the pathway where renal registries can contribute. R&D = research and 
development. Adapted from reference 25. 
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